Navigation Links
Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
Date:5/14/2008

PITTSBURGH, May 14 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has launched Paroxetine Hydrochloride (HCl) Extended-release (ER) Tablets, the generic version of GlaxoSmithKline's (GSK) Paxil CR(R). As the first company to successfully file an abbreviated new drug application (ANDA) containing a paragraph IV certification for the 12.5 mg and 25 mg tablets, Mylan has earned 180 days of marketing exclusivity for these two strengths. Reflecting a supply and distribution agreement with GSK, Mylan also has the right to market the 37.5 mg strength. Mylan is not aware of any other ANDA filers with paragraph IV certifications for this product.

"As another first-to-file opportunity, Paroxetine HCl ER reflects Mylan's continued dynamic speed-to-market capabilities," says Robert J. Coury, Mylan's vice chairman and CEO. "Because this product also belongs in the 'difficult- to-manufacture' category, it is yet another example of our historically strong R&D process, through which we're able to deliver affordable versions of important complex therapies. Our settlement with GSK is consistent with our commitment to monetize opportunities when it benefits both patients and our shareholders."

Paroxetine HCl ER Tablets had U.S. sales of approximately $301 million for the 12 months ending March 31, 2008, for all three strengths.

In October 2007, Mylan announced the settlement of patent litigation involving Paroxetine HCl ER. At that time, Mylan stated that the settlement would provide the company with patent licenses and the right to market all three strengths beginning no later than Oct. 1, 2008. As part of the settlement agreement, which remains confidential, Mylan has been provided with the patent licenses needed to distribute the product immediately.

Mylan Inc., with a presence in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
2. Mylan Declares Quarterly Preferred Stock Dividend
3. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
4. Mylan Announces Final FDA Approval for Trandolapril Tablets
5. Mylan Announces Final FDA Approval for Felodipine Extended-Release Tablets, USP
6. Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
7. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
8. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
9. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
10. Mylan Restores Availability of Generic Levothyroxine in Florida
11. Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... An inventor from Salisbury, N.C., ... haven’t yet seen an effective and dignified way to keep leeches in place during ... CUP." , This invention provides an effective way to keep a leech in place ...
(Date:7/26/2017)... ... July 26, 2017 , ... A major challenge many labs ... freeze drying samples and a lengthy freeze dry cycle are a few common challenges ... drying techniques, as well as new accessories and advancements in laboratory freeze dryers that ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... the cloud ; today announced the availability of its latest data protection solution ... use control console for Data Discovery, Classification, Encryption and Digital Rights Management; GTB ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... or “Isodiol”) a global cannabis innovator, specializing in the development of pharmaceutical and ... from April 1, 2017 to June 30, 2017. Iso International LLC recorded unaudited ...
(Date:7/25/2017)... St. Louis, MO (PRWEB) , ... July 25, 2017 , ... ... (HDIS) in St. Louis, Missouri. The company has achieved record-breaking sales for ... multiple departments over the next 12 months. , The upcoming year offers excitement and ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... EXTON, Pa., July 27, 2017  West Pharmaceutical Services, ... financial results for the second-quarter 2017 and updated financial ... Second-Quarter 2017 Highlights Reported ... 2.5% over the prior-year quarter. Net sales at constant ... 2017 reported-diluted EPS was $0.51, compared to $0.60 in ...
(Date:7/26/2017)... NEW YORK , July 26, 2017 ... Annual Prix Galien USA Award ... honors, the Prix Galien Award recognizes outstanding biomedical and technology ... To qualify, each candidate must be ... the last five years and demonstrate tremendous potential to impact ...
(Date:7/24/2017)... 24, 2017  Diplomat Pharmacy, Inc. (NYSE: ... second quarter 2017 operating results on Monday, August 7, ... follow at 5:00 p.m. ET. ... a live broadcast of the conference call by dialing ... code 51641230 approximately 15 minutes prior to the call. ...
Breaking Medicine Technology: